Detalles de la búsqueda
1.
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.
Respir Res
; 25(1): 107, 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38419035
2.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Br J Clin Pharmacol
; 87(2): 598-611, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32520410
3.
Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
Br J Clin Pharmacol
; 87(5): 2303-2320, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125753
4.
A Pilot Study to Assess the Feasibility of Collecting and Transmitting Clinical Trial Data with Mobile Technologies.
Digit Biomark
; 2(3): 126-138, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-32095763
Resultados
1 -
4
de 4
1
Próxima >
>>